Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 2014. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility (PDMRs), and connected persons under the UK Disclosure and Transparency Rules (DTR 3.1.4R).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a regulatory disclosure of share acquisitions and does not contain financial performance data.
Material Changes
On November 11, 2014, several GSK Directors and PDMRs acquired Ordinary Shares through the GSK ShareReward Plan. The transaction price was 1,440.25 pence per share. The acquisitions consisted of both personal contributions and matching contributions from GSK.
- Directors/PDMRs: Sir Andrew Witty, Mr R G Connor, Mr S Dingemans, Mr N Hirons, Mr D S Redfern, Ms C Thomas, Mr P C Thomson, Dr P J T Vallance, and Mrs V A Whyte each acquired 8 or 9 shares under both the personal and matching elements.
- Connected Person: Mrs K Thomson (connected to Mr P C Thomson) acquired 1 share under both elements.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the reporting of specific share transactions.
Investor Verification Checklist
- Verify the total number of shares acquired by each Director and PDMR listed in the ShareReward Plan.
- Confirm the transaction price of 1,440.25 pence per share against market data for November 11, 2014.
- Review the specific terms of the GSK ShareReward Plan to understand the matching contribution structure.
- Check subsequent filings for any changes in director shareholdings or additional transactions.